Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of NIS793 + gemcitabine + nab-paclitaxel in first-line metastatic pancreatic ductal adenocarcinoma
2021-000591-10Phase 3Completed
- Sponsor
- Novartis
- Start
- Aug 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pancreatic adenocarcinoma (PDAC) and pancreatic cancer (PC) comparing NIS793 + gemcitabine + nab-paclitaxel with Placebo + gemcitabine + nab-paclitaxel (2 arms). Primary endpoint: Incidence of dose-limiting toxicities (DLTs) in the first cycle (safety run-in). Started Aug 2021; status: completed.
02
Drugs
nisevokitug
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic cancer (PC)
Beyond the preview
Go deeper on 2021-000591-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000591-10.